Success Metrics

Clinical Success Rate
84.9%

Based on 389 completed trials

Completion Rate
85%(389/458)
Active Trials
71(10%)
Results Posted
46%(177 trials)
Terminated
69(10%)

Phase Distribution

Ph phase_2
133
19%
Ph phase_3
57
8%
Ph early_phase_1
32
5%
Ph phase_4
194
28%
Ph phase_1
88
13%
Ph not_applicable
147
21%

Phase Distribution

120

Early Stage

133

Mid Stage

251

Late Stage

Phase Distribution651 total trials
Early Phase 1First-in-human
32(4.9%)
Phase 1Safety & dosage
88(13.5%)
Phase 2Efficacy & side effects
133(20.4%)
Phase 3Large-scale testing
57(8.8%)
Phase 4Post-market surveillance
194(29.8%)
N/ANon-phased studies
147(22.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

77.8%

389 of 500 finished

Non-Completion Rate

22.2%

111 ended early

Currently Active

71

trials recruiting

Total Trials

684

all time

Status Distribution
Active(89)
Completed(389)
Terminated(111)
Other(95)

Detailed Status

Completed389
unknown90
Terminated69
Recruiting57
Withdrawn42
Active, not recruiting14

Development Timeline

Analytics

Development Status

Total Trials
684
Active
71
Success Rate
84.9%
Most Advanced
Phase 4

Trials by Phase

Early Phase 132 (4.9%)
Phase 188 (13.5%)
Phase 2133 (20.4%)
Phase 357 (8.8%)
Phase 4194 (29.8%)
N/A147 (22.6%)

Trials by Status

recruiting578%
terminated6910%
withdrawn426%
suspended51%
unknown9013%
enrolling_by_invitation41%
completed38957%
active_not_recruiting142%
not_yet_recruiting142%

Recent Activity

Clinical Trials (684)

Showing 20 of 684 trialsScroll for more
NCT07680140Phase 4

Biomarker-Guided Antidepressant Selection

Recruiting
NCT03065335Phase 1

Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder

Recruiting
NCT04600089Phase 2

Ketamine in Patients Undergoing TEVAR Procedures Receiving NCI

Completed
NCT03362073Phase 2

Continuous IntraVenous Infusion of Ketamine in Terminally Ill Cancer Patients

Terminated
NCT06480201Phase 1

Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression

Recruiting
NCT06364540Phase 4

Nebulized Ketamine to Nebulized Fentanyl for Treating Acute Painful Conditions in the ED

Recruiting
NCT07370181Phase 3

Ketamine Irrigation Analgesia in Laparoscopic Cholecystectomy

Active Not Recruiting
NCT05737693Phase 2

Enhancing Week-long Psychological Treatment for PTSD With Ketamine

Active Not Recruiting
NCT05233566Phase 3

Ketamine for Postoperative Avoidance of Depressive Symptoms: The K-PASS Feasibility Trial

Completed
NCT06179485

Effect of Ketamine and Etomidate During RSI on Long Term Outcomes

Enrolling By Invitation
NCT05401227Phase 1

Glutamatergic Mechanisms: Aim2

Recruiting
NCT07768618Phase 2

Electrophysiologic Mechanisms of Ketamine Antidepressant Response

Not Yet Recruiting
NCT06781697Phase 3

InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression

Recruiting
NCT05086250Early Phase 1

Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer

Completed
NCT02624596Phase 2

Understanding How Ketamine Brings About Rapid Improvement in OCD

Completed
NCT06538285Phase 2

Ketamine-Assisted Recovery for Methamphetamine Use Disorder & HIV

Completed
NCT04560660Phase 2

Ketamine-enhanced Prolonged Exposure Therapy in PTSD

Completed
NCT06868589Phase 4

Reducing Pain With Methadone and Ketamine in Liver Transplant

Completed
NCT07705022Phase 2

Assessing Covert Consciousness During Dexmedetomidine and Ketamine Sedation: An fMRI Study

Enrolling By Invitation
NCT03427736

Anesthetics and Analgesics in Children

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
684